Evidence map›Paper›PMID 31745905›Full record

ArticleJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2020

Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice?

Ashley N Krepline, Lindsay Bliss, Jennifer Geurts, Idayat Akinola, Kathleen K Christians, Ben George, Paul S Ritch, William A Hall, Beth A Erickson, Douglas B Evans and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ashley N KreplineDepartment of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA.
Lindsay BlissDepartment of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA.
Jennifer GeurtsDepartment of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA.
Idayat AkinolaDepartment of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA.
Kathleen K ChristiansDepartment of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA.
Ben GeorgeDepartment of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Paul S RitchDepartment of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
William A HallDepartment of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Beth A EricksonDepartment of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Douglas B EvansDepartment of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA.
Susan TsaiDepartment of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA. stsai@mcw.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTumor profiling can improve the selection of oncologic therapies in patients with pancreatic cancer (PC). The impact of neoadjuvant therapy on tumor testing is unknown.

methodsMolecular profiling using commercially available 53-, 315-, or 472-gene next generation sequencing (NGS) panels was performed on surgical specimens following neoadjuvant therapy. All specimens with 472-gene sequencing also had immunohistochemical (IHC) testing. Treatment recommendations were based on somatic variants and IHC staining.

resultsNGS was performed on 74 patient specimens: 42 (57%) with a 472-gene panel, 28 (38%) with a 315-gene panel, 3 (4%) had 472- and 315-gene panels, and 1 (1%) patient had 53- and 472-gene panels (78 total tests). Likely pathogenic/pathogenic variants were identified in 73 (94%) of the 78 tests. Of the 73 samples with variants identified, 13 (18%) variants were associated with an actionable treatment: ATM (n = 10), BRCA1 (n = 1), PIK3CA (n = 1), and BRCA2 (n = 1). No patient had more than one actionable variant. Based on NGS results, the most commonly recommended therapy was a platinum agent (n = 12/78, 15%). Of the 46 specimens that underwent IHC analysis, overlapping chemotherapeutic treatment recommendations were identified in 40 (87%) specimens.

conclusionUsing current multigene NGS panels, actionable variants were identified in 13 (18%) of 74 surgical specimens and primarily involved genes of the DNA repair pathway. Anecdotal reproducibility of test concordance was low.

Indexed as

Biomarkers, TumorBRCA1 ProteinBRCA2 ProteinDNA, NeoplasmHigh-Throughput Nucleotide SequencingHumansNeoadjuvant TherapyPancreatic NeoplasmsReproducibility of ResultsBiomarkers, TumorBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanDNA, NeoplasmMolecular profilingNext generation sequencingPancreatic cancerTargeted therapy

Identifiers

PMID31745905

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.